<DOC>
	<DOC>NCT00517699</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of MabThera plus high dose methotrexate plus high dose cytarabine in patients with central nervous system non-Hodgkin's lymphoma. Eligible patients will receive a treatment regimen consisting of MabThera (750mg/m2 iv) plus methotrexate (8g/m2 iv) given at intervals up to week 22, plus cytarabine (2g/m2 iv) at week 11 and week 22. The anticipated time on study treatment is 3-12 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>adult patients, 1880 years of age; histological diagnosis of primary central nervous system lymphoma; Bcell proliferation verified by positive staining for CD20; &gt;=1 measurable lesion. prior chemotherapy, other than corticosteroids, &gt;=6 weeks before and after diagnosis or surgery; history of prior cranial irradiation; evidence of plurisystemic nonHodgkin's lymphoma; other active malignant disease (other than basal cell or squamous cell cancer of skin,or cancer in situ of cervix; uncontrolled active infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>